05:39 PM EST, 11/03/2025 (MT Newswires) -- Xenon Pharmaceuticals ( XENE ) reported a Q3 net loss late Monday of $1.15 per diluted share, widening from the loss of $0.81 a year earlier.

Analysts polled by FactSet also expected a loss of $1.15.

Based on current operating plans, the company said it expects

having sufficient cash to fund operations into 2027.

Shares were down more than 5% in after-hours activity.